Clinical efficacy of Xueping tablet in the treatment of abnormal uterine bleeding related to endometrial causes (AUB-E): a randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054158

Enrollment

Unknown

Registered

2021-12-10

Start date

2021-12-15

Completion date

Unknown

Last updated

2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abnormal uterine bleeding

Interventions

Xueping tablet treatment group:Xueping tablet

Western medicine control group:Tranexamic acid tablets

Eligibility

Sex/Gender

Female

Age

18 Years to 48 Years

Inclusion criteria

Inclusion criteria: 1. Patients with clinically diagnosed ABU-E; 2. No serious dysfunction of heart, liver, kidney and other important organs; 3. Aged 18-48 years; 4. Unwilling to use sex hormone therapy; 5. Unwilling to use contraceptive ring LNGIUS; 6. Unwilling to accept conservative surgery; 7. Voluntary participation and signing of informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with hypothyroidism; 2. Poor compliance; 3. Pregnant women or patients with recent fertility preparation; 4. Patients with interphase bleeding as the main bleeding mode.

Design outcomes

Primary

Measure	Time frame
Effective rate of clinical efficacy evaluation;	—

Secondary

Measure	Time frame
Number of sanitary napkins used per menstrual cycle;	—

Countries

China

Contacts

Public ContactZhang Mingmin

Tongji Hospital, Tongji Medicine College, Huazhong University of Science and Technology

mmzhang@tjh.tjmu.edu.cn+86 13995675011

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026